Source=<a href="http://www.ott.nih.gov/sites/default/files/documents/docs/nih-iia-nih-lead-model-102005.docx">Word Doc</a>

=[01/Agt/Frame/Library_Plus1]
P1.the={m-}the NIH{-m}
P1.The={m-}The NIH{-m}
P2.the={m-}the Institition{-m}
P2.The={m-}The Institition{-m}


Agt.Title=Inter-Institutional Agreement - {P1.Handle}-Lead

Agt.Secs=<ol><li>{Why.Sec}</li><li>{Def.Sec}</li><li>{Grant.Sec}</li><li>{Prosecute.Sec}</li><li>{Sublicense.Sec}</li><li>{Comp.Sec}</li><li>{Report.Sec}</li><li>{Infringe.Sec}</li><li>{Dispute.Sec}</li><li>{Time.Sec}</li><li>{Misc.Sec}</ol>

Why.Sec=<b>{Why.Title}</b><ol><li>{Why.1}</li><li>{Why.2}</li></ol>

Why.Title=BACKGROUND

Why.1=In the course of {Invent.Background}, {Inventor.List} (hereinafter referred to as the &ldquo;Inventor(s)&rdquo;) made or reduced to practice certain inventions, which are included within the Patent Rights, as defined in Paragraph 2.1.

Why.2=It is the mutual desire of {P2.the} and {P1.the} that their respective undivided interests in the Patent Rights be administered in a manner to ensure the rapid commercialization of the Patent Rights and to make their benefits widely available to the public.  

Why.Grant=Therefore, {P2.the} is granting an exclusive license under {P2.the}'s rights in the Patent Rights to {P1.the} under the conditions set forth herein.


Def.Sec=<b>{Def.Title}</b><ol type"none"><li>{Def.Government}</li><li>{Def.FDA}</li><li>{Def.Patent_Rights}</li><li>{Def.Net_Revenues}</li><li>{Def.Expenses}</li></ol>

Def.Title=DEFINITIONS

Def.Government=&ldquo;Government&rdquo; means the government of the United States of America.
Def.FDA=&ldquo;FDA&rdquo; means the Food and Drug Administration.
Def.Patent_Rights=&ldquo;Patent Rights&rdquo; means:<ol type="a"><li>{Def.Patent_Rights.1}</li><li>{Def.Patent_Rights.2}</li><li>{Def.Patent_Rights.3}</li><li>{Def.Patent_Rights.4}</li></ol>

Def.Patent_Rights.1=Patent applications (including provisional patent applications and PCT patent applications) or patents as follows: {Patent.Identification}, and any patent application(s) claiming the benefit of priority thereof including all divisions and continuations of these applications, all patents issuing from such applications, divisions, and continuations, and any reissues, reexaminations, and extensions of all such patents to the extent that at least one Inventor from {P2.the} is an Inventor thereon;

Patent.Identification={m-}{Patent1.Identification}{-m}

Patent1.Identification=U.S. Patent Application Serial No./U.S. Provisional Patent Application Serial No. ____/______,______, filed ________________, entitled ________________________
Def.Patent_Rights.2=to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.3(a) and to the extent that at least one Inventor from {P2.the} is an Inventor:<ol><li>{Def.Patent_Rights.2.1};</li><li>{Def.Patent_Rights.2.2};</li><li>{Def.Patent_Rights.2.3};</li><li>{Def.Patent_Rights.2.4}; and</li><li>{Def.Patent_Rights.2.5}</li></ol>
Def.Patent_Rights.2.1=continuations in part of 2.3(a)
Def.Patent_Rights.2.2=all divisions and continuations of these continuations in part
Def.Patent_Rights.2.3=all patents issuing from these continuations in part, divisions, and continuations
Def.Patent_Rights.2.4=priority patent application(s) of 2.3(a)
Def.Patent_Rights.2.5=any reissues, reexaminations, and extensions of all these patents; and

Def.Patent_Rights.3=to the extent that the following contain one or more claims directed to the invention or inventions disclosed in 2.3(a) and to the extent that at least one Inventor from {P2.the} is an Inventor: all counterpart foreign and U.S. patent applications and patents to 2.3(a) and 2.3(b); and
Def.Patent_Rights.4=Patent Rights shall not include 2.3(b) or 2.3(c) to the extent that they contain one or more claims directed to new matter which is not the subject matter disclosed in 2.3(a).

Def.Net_Revenues=&ldquo;Net Revenues&rdquo; means all consideration received by {P1.the} from the licensing of the Patent Rights pursuant to this Agreement less (a) Expenses and then (b) fifteen percent (15%) of the remaining consideration for administrative overhead.  In the event that a license is executed by {P1.the} with a third party wherein the Patent Rights are licensed together with other technologies not falling under the definition of the Patent Rights, all consideration received by {P1.the} from the licensing of the Patent Rights pursuant to this Agreement through the third-party executed license shall correspond to the Patent Rights&rsquo; percentage contribution to the total amount received for all licensed technologies as determined by {P1.the}.

Def.Expenses=&ldquo;Expenses&rdquo; means all reasonable and actual out-of-pocket costs, excluding those reimbursed by a third party, paid by {P1.the} for the preparation, filing, prosecution, and licensing of United States and foreign patent applications, extraordinary expenses as provided in Paragraph 4.6, and the maintenance of the resulting patents or patent applications, exclusive of any salaries, administrative, or other indirect costs.


Grant.Sec=<b>{Grant.Title}</b><ol><li>{Grant.1}</li><li>{Grant.2}</li></ol>

Grant.Title=GRANT AND RESERVATION OF RIGHTS

Grant.1={P2.The} hereby grants and {P1.the} accepts, subject to the terms and conditions of this Agreement, an exclusive license including the right to sublicense, under the Patent Rights to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any tangible embodiment of the Patent Rights and to practice and have practiced any process(es) included within the Patent Rights.

Grant.2=The Government shall have the irrevocable, royalty-free, paid-up right to practice and have practiced the Patent Rights throughout the world by or on behalf of the Government and on behalf of any foreign government or international organization pursuant to any existing or future treaty or agreement to which the Government is a signatory.


Prosecute.Sec=<b>{Prosecute.Title}</b><ol><li>{Prosecute.1}</li><li>{Prosecute.2}</li><li>{Prosecute.3}</li><li>{Prosecute.4}</li><li>{Prosecute.5}</li><li>{Prosecute.6}</li></ol>

Prosecute.Title=PATENT PROSECUTION AND PROTECTION

Prosecute.1={P1.The} shall file, prosecute, and maintain patent application(s) relating to the Patent Rights and shall promptly provide to {P2.the} all serial numbers and filing dates, together with copies of all the applications, including copies of all Patent Office actions, responses, and all other Patent Office communications.  In addition, {P2.the} shall be granted Power of Attorney for all such patent applications.  {P1.The} shall consult with {P2.the}, when so requested, prior to communicating with any Patent Office with respect to the Patent Rights.

Prosecute.2={P1.The} shall make an election with respect to foreign filing, upon consultation with {P2.the}.  If any foreign patent applications are filed, {P1.the} shall promptly provide to {P2.the} all serial numbers and filing dates.  {P1.The} also shall provide to {P2.the} copies of foreign patent applications and Patent Office actions.  {P1.The} shall consult with {P2.the}, when so requested, prior to communication with any Patent Office with respect to the Patent Rights. 

Prosecute.3={P1.The} shall promptly record Assignments of domestic patent rights in the United States Patent and Trademark Office and shall promptly provide {P2.the} with a photocopy of each recorded Assignment(s) to {P2.the}.

Prosecute.4=Notwithstanding any other provision of this Agreement, {P1.the} shall not abandon the prosecution of any patent application, including provisional patent applications (except for purposes of filing continuation application(s)) or the maintenance of any patent contemplated by this Agreement, without prior written notice to {P2.the}.  Upon receiving the written notice, {P2.the} may, at its sole option and expense, take over the prosecution of any patent application, or the maintenance of any patent.

Prosecute.5={P1.The} shall promptly provide {P2.the} with copies of all issued patents under this Agreement.

Prosecute.6=In the event that {P1.the} anticipates the possibility of any extraordinary expenditures arising from the preparation, filing, prosecution, licensing, or defense of any patent application or patent contemplated by this Agreement, including, without limitation, interferences, reexaminations, reissues and oppositions, {P1.the} shall provide {P2.the} with all relevant information and these extraordinary expenditures shall be included as Expenses only upon written agreement of {P2.the}.  {P1.The} and {P2.the} shall agree on a mutually acceptable course of action prior to incurring these expenditures.

Sublicense.Sec=<b>{Sublicense.Title}</b><ol><li>{Sublicense.1}</li><li>{Sublicense.2}</li></ol>

Sublicense.Title=LICENSING
Sublicense.1={P1.The} shall diligently seek licensees for the commercial development of the Patent Rights and shall administer the Patent Rights for the mutual benefit of the parties and in the public interest.

Sublicense.2={P1.The} shall promptly provide {P2.the} with copies of all licenses and sublicenses granted for the Patent Rights.


Comp.Sec=<b>{Comp.Title}</b><ol><li>{Comp.1}</li><li>{Comp.2}</li><li>{Comp.3}</li><li>{Comp.4}</li></ol>

Comp.Title=ROYALTIES AND EXPENSES

Comp.1={P1.The} shall distribute Net Revenues to {P2.the} concurrently with distributions it makes under {P1.the}'s patent policy on the following basis: (a) {Comp.Royalty.P2.%} of the Net Revenues as a royalty to {P2.the} and (b) {Comp.Royalty.P1.%} of the Net Revenues as a royalty to {P1.the}.  All payments to {P2.the}, required under this Agreement, shall be in U.S. dollars and shall be made by check or bank draft drawn on a United States bank and made payable to {P2.Pay.Name.Full}.  All payments shall be sent to the following address:  {P2.Pay.Addr.N,A}.

Comp.2={P1.The} shall submit to {P2.the} annual statements of itemized Expenses, as defined in Paragraph 2.5, and shall deduct the Expenses as provided for in Paragraph 2.4, except where {P2.the} has identified discrepancies in billing by {P1.the}, in which case, deduction of the contested item(s), as a part of Expenses as provided for in Paragraph 2.4, shall be delayed pending resolution thereof.

Comp.3=In no event shall {P2.the} be obligated to bear any costs for the Expenses under this Agreement.

Comp.4=Each party shall be solely responsible for calculating and distributing to its respective Inventor(s) of the Patent Rights any share of the Net Revenues in accordance with its respective patent policy, royalty policy, or Federal law during the term of this Agreement.

Report.Sec=<b>{Report.Title}</b><ol><li>{Report.1}</li><li>{Report.2}</li></ol>

Report.Title=RECORDS AND REPORTS

Report.1={P1.The} shall keep complete, true, and accurate accounts of all Expenses and of all Net Revenues received by it from each licensee of the Patent Rights and shall permit {P2.the} or {P2.the}'s designated agent to examine its books and records in order to verify the payments due or owed under this Agreement.  This examination shall not occur more than one (1) time in any single calendar year.

Report.2=Upon request by {P2.the}, {P1.the} shall submit to {P2.the} a report, not later than April 1 of each year, setting forth the status of all patent prosecution, commercial development, and licensing activity relating to the Patent Rights for the preceding calendar year.

Infringe.Sec=<b>{Infringe.Title}</b><ol><li>{Infringe.1}</li><li>{Infringe.2}</li><li>{Infringe.3}</li><li>{Infringe.4}</li><li>{Infringe.5}</li></ol>

Infringe.Title=PATENT INFRINGEMENT

Infringe.1=In the event {P1.the} or {P2.the}, including its licensees, shall learn of the substantial infringement of any patent subject to this Agreement, the party who learns of the infringement shall promptly notify the other party in writing and shall provide the other party with all available evidence of the infringement.  {P1.The} and its licensees, in cooperation with {P2.the}, shall use their best efforts to eliminate the infringement without litigation.  If the efforts of the parties are not successful in eliminating the infringement within ninety (90) days after the infringing party has been formally notified of the infringement by {P1.the}, {P1.the} shall have the right, after consulting with {P2.the}, to commence suit on its own account.  {P2.The} may commence its own suit after consultation with {P1.the}.

Infringe.2={P1.The} may permit its licensees to bring suit on their own account, and {P1.the} shall retain the right to join any licensee's suit.

Infringe.3={P2.The} shall take no action to compel {P1.the} either to initiate or to join in any suit for patent infringement.  Should the Government be made a party to any such suit by motion or any other action of {P2.the}, {P2.the} shall reimburse the Government for any costs, expenses, or fees which the Government incurs as a result of the motion or other action, including all costs incurred by {P1.the} in opposing any joinder action.

Infringe.4=Legal action or suits to eliminate infringement or recover damages pursuant to Paragraph 8.1 shall be at the full expense of the party by whom suit is brought.  All damages recovered thereby shall first be used to reimburse each party for its expenses related to the legal action or suit, and the remainder of the damages shall be considered Net Revenues.

Infringe.5=Each party agrees to cooperate with the other in litigation proceedings.  {P1.The} may be represented, at its expense, by counsel of its choice in any suit.

Dispute.Sec=<b>{Dispute.Title}</b><ol><li>{Dispute.1}</li><li>{Dispute.2}</li></ol>

Dispute.Title=GOVERNING LAWS, SETTLING DISPUTES

Dispute.1=This Agreement shall be construed in accordance with U.S. Federal law, as interpreted and applied by the U.S. Federal courts in the District of Columbia.  Federal law and regulations shall preempt any conflicting or inconsistent provisions in this Agreement.  {P2.The} agrees to be subject to the jurisdiction of U.S. courts.

Dispute.2=Any controversy or any disputed claim by either party against the other arising under or related to this Agreement shall be submitted jointly to {P2.the}&rsquo;s President or designee and to the Director of {P1.the} or designee for resolution.  {P2.The} and {P1.the} shall be free after written decisions are issued by those officials to pursue any and all administrative or judicial remedies which may be available.

Time.Sec=<b>{Time.Title}</b><ol><li>{Time.1}</li><li>{Time.2}</li><li>{Time.3}</li><li>{Time.4}</li></ol>

Time.Title=TERM AND TERMINATION

Time.1=This Agreement is effective when signed by all parties, unless the provisions of Paragraph 11.8 are not fulfilled, and shall extend to the expiration of the last to expire of the patents included within the Patent Rights unless otherwise terminated by operation of law or by acts of the parties in accordance with the terms of this Agreement.

Time.2={P1.The} may terminate this Agreement upon at least sixty (60) days written notice to {P2.the}, but in any event, not less than sixty (60) days prior to the date on which any pending Patent Office actions need be taken to preserve patent rights for the benefit of the parties hereto.

Time.3={P2.The} may terminate this Agreement in whole or in part if:<ol><li>{Time.3.1}</li><li>{Time.3.2}</li><li>{Time.3.3}</li></ol>

Time.3.1=the  {P1.Handle} fails to make payments or periodic reports required by this Agreement;

Time.3.2=the  {P1.Handle} has committed a substantial breach of a covenant or duty contained in this Agreement; or

Time.3.3={P1.the} and {P2.the} are involved in a dispute under this Agreement which cannot be resolved under the procedures specified in Paragraph 9.2.

Time.4=If the Agreement is terminated under Paragraph 10.3, {P2.the} agrees to provide all affected licensees an opportunity to license the Patent Rights under such terms as may have been agreed to by {P1.the}.

Misc.=[01/Agt/Type/License/Patent/NIH/OTT/Sec/Inter-Institutional_NIH-Lead_Misc.md]

Agt.Sign.Intro=IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate originals by their respective duly authorized officers hereunto, on the day and year hereinafter written.  Any communication or notice to be given shall be forwarded to the respective addresses listed below.


TO BE COMPLETED:

For {P1.the}:
_______________ DRAFT ____________________________	_______________
Richard U. Rodriguez	Date
Director, Division of Technology Development and Transfer
Office of Technology Transfer
National Institutes of Health
Mailing Address or E-mail Address for Agreement notices and reports:
Chief, Monitoring & Enforcement Branch
Office of Technology Transfer
National Institutes of Health
6011 Executive Boulevard, Suite 325
Rockville, Maryland  20852-3804 U.S.A.
E-mail: LicenseNotices_Reports@mail.nih.gov
For {P2.the} (Upon information and belief, the undersigned expressly certifies or affirms that the contents of any statements of {P2.the} made or referred to in this Agreement are truthful and accurate.)
by:
________________ DRAFT ___________________________	_______________
Signature of Authorized Official		Date
	
Printed Name
	
Title
Official and Mailing Address for Agreement notices:
	
Name
	
Title
Mailing Address:
	
	
	
	
Email Address:		
Phone:		
Fax:		
Official and Mailing Address for Financial notices ({P2.The}&rsquo;s contact person for royalty payments)
	
Name
	
Title
Mailing Address:
	
	
	
	
Email Address:		
Phone:		
Fax:		

Agt.Attach={WarningAgainstPerjury}

WarningAgainstPerjury=Any false or misleading statements made, presented, or submitted to the Government, including any relevant omissions, under this Agreement and during the course of negotiation of this Agreement are subject to all applicable civil and criminal statutes including Federal statutes 31 U.S.C. §§3801-3812 (civil liability) and 18 U.S.C. §1001 (criminal liability including fine(s) or imprisonment).